Massive Bio, a global leader in AI-driven cancer clinical trial enrollment, has launched Patient Connect, a new free portal designed to streamline cancer patients’ access to clinical trials worldwide.
Patient Connect allows patients to find suitable clinical trials in their preferred language. By granting access to their medical records, patients enable Massive Bio’s AI-powered system to match them with trials based on their specific diagnosis, biomarkers, treatment history, and location. This tool expands access to treatment options, overcoming financial and geographic barriers. Patients can download their personalized trial matching reports and share them with their physicians and loved ones for informed decision-making.
With Patient Connect, over 132,000 patients can access personalized results for nearly 16,000 cancer trials. Massive Bio has matched patients to over 33,000 clinical trial sites, showcasing the effectiveness of its AI platform. Recent ASCO 2024 research with the Precision Cancer Consortium demonstrated that this multi-trial matching approach can increase patient eligibility for trials by up to 12 times.
Dr. Arturo Loaiza-Bonilla, Chief Medical Officer and Co-Founder of Massive Bio, commented, “Patient Connect transforms patient engagement with clinical trials, providing new treatment options and hope for better outcomes.”
The portal also offers personalized support through concierge services. Patient relations coordinators, MDs, and oncology nurses assist with enrollment, referrals, and addressing logistical and financial concerns, ensuring a seamless transition to trial participation.
Oz Hüner, Chief Product Officer of Massive Bio, added, “Patient Connect makes navigating the clinical trial process intuitive, keeping patients connected to their physicians and loved ones.”
Massive Bio’s Clinical Network also enables oncologists and hematologists to review pre-screening results and manage patient enrollment, integrating patient and provider engagement to boost global clinical trial enrollment.
About Massive Bio:
Massive Bio is revolutionizing the pharmaceutical value chain with AI-driven solutions that enhance the patient journey and optimize drug development and commercialization. Founded in 2015, the company has collaborated with over four dozen pharmaceutical companies and research organizations. As a founding member of CancerX and participant in the Cancer Moonshot initiative, Massive Bio is dedicated to improving access to clinical trials and facilitating value-based oncology decisions. With a global team of over 100 employees in 17 countries, Massive Bio continues to lead in advancing cancer treatment.
